The North America Veterinary Pain Management Market should witness market growth of 5.5% CAGR during the forecast period (2023-2030).
Veterinary treatment must have effective pain management. When pain is not properly managed in animals, sick animals experience increased stress and delayed healing. Animals may experience pain from operation, arthritis, or cancer, accompanied by discrimination, starvation, and reduced activity. This may hamper the productivity of agricultural and companion animals. Due to ongoing research on reducing chronic pain in animals, numerous methods are now available, including painkillers, physical therapy, acupuncture, laser therapy, and therapeutic massage.
Due to the rise in pet adoption as companions, which raises the demand for preventative care, medications, and veterinary healthcare facilities, the market has been expanding significantly. The prevalence of animal diseases that cause discomfort and inflammation is another factor driving market expansion. Additionally, it is projected that the increasing popularity of alternative and non-pharmaceutical treatments and untapped growing markets would offer additional growth opportunities.
The market in the North America region is anticipated to expand due to factors including growing adoption of pets and rising per capita spending on veterinary treatment for animals in the region. The primary cause of the market's expansion has been recognized as the increase in the occurrence of numerous animal diseases and injuries. The number of pets and livestock owners in the US has increased, and people have become more aware of the welfare of these animals. Therefore, the market is anticipated to experience considerable growth over the forecast period in North America due to the increasing awareness of and spending on animal health. The prevalence of inflammatory disorders in animals is increasing, along with all of the above factors; thus, the market is projected to expand over the coming years.
The US market dominated the North America Veterinary Pain Management Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $625 million by 2030. The Canada market is poised to grow at a CAGR of 7.9% during (2023-2030). Additionally, The Mexico market should witness a CAGR of 6.9% during (2023-2030).
Based on Animal type, the market is segmented into Livestock Animal and Companion Animal. Based on End-Use, the market is segmented into Hospitals & Clinics and Others. Based on Indication, the market is segmented into Osteoarthritis, Post-operative pain, and Others. Based on Product, the market is segmented into NSAIDs, Opioids, Anesthetics and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Bayer AG, Zoetis, Inc., Merck & Co., Inc., Elanco Animal Health, Inc., Zomedica Corp. (Assisi Animal Health), Norbrook Laboratories Limited, Ceva Santé Animale, Dechra Pharmaceuticals PLC, and Vetoquinol SA (Soparfin SCA)
Veterinary treatment must have effective pain management. When pain is not properly managed in animals, sick animals experience increased stress and delayed healing. Animals may experience pain from operation, arthritis, or cancer, accompanied by discrimination, starvation, and reduced activity. This may hamper the productivity of agricultural and companion animals. Due to ongoing research on reducing chronic pain in animals, numerous methods are now available, including painkillers, physical therapy, acupuncture, laser therapy, and therapeutic massage.
Due to the rise in pet adoption as companions, which raises the demand for preventative care, medications, and veterinary healthcare facilities, the market has been expanding significantly. The prevalence of animal diseases that cause discomfort and inflammation is another factor driving market expansion. Additionally, it is projected that the increasing popularity of alternative and non-pharmaceutical treatments and untapped growing markets would offer additional growth opportunities.
The market in the North America region is anticipated to expand due to factors including growing adoption of pets and rising per capita spending on veterinary treatment for animals in the region. The primary cause of the market's expansion has been recognized as the increase in the occurrence of numerous animal diseases and injuries. The number of pets and livestock owners in the US has increased, and people have become more aware of the welfare of these animals. Therefore, the market is anticipated to experience considerable growth over the forecast period in North America due to the increasing awareness of and spending on animal health. The prevalence of inflammatory disorders in animals is increasing, along with all of the above factors; thus, the market is projected to expand over the coming years.
The US market dominated the North America Veterinary Pain Management Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $625 million by 2030. The Canada market is poised to grow at a CAGR of 7.9% during (2023-2030). Additionally, The Mexico market should witness a CAGR of 6.9% during (2023-2030).
Based on Animal type, the market is segmented into Livestock Animal and Companion Animal. Based on End-Use, the market is segmented into Hospitals & Clinics and Others. Based on Indication, the market is segmented into Osteoarthritis, Post-operative pain, and Others. Based on Product, the market is segmented into NSAIDs, Opioids, Anesthetics and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Bayer AG, Zoetis, Inc., Merck & Co., Inc., Elanco Animal Health, Inc., Zomedica Corp. (Assisi Animal Health), Norbrook Laboratories Limited, Ceva Santé Animale, Dechra Pharmaceuticals PLC, and Vetoquinol SA (Soparfin SCA)
Scope of the Study
By Animal type
- Livestock Animal
- Companion Animal
By End-Use
- Hospitals & Clinics
- Others
By Indication
- Osteoarthritis
- Post-operative pain
- Others
By Product
- NSAIDs
- Opioids
- Anesthetics
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Boehringer Ingelheim International GmbH
- Bayer AG
- Zoetis, Inc.
- Merck & Co., Inc.
- Elanco Animal Health, Inc.
- Zomedica Corp. (Assisi Animal Health)
- Norbrook Laboratories Limited
- Ceva Santé Animale
- Dechra Pharmaceuticals PLC
- Vetoquinol SA (Soparfin SCA)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. North America Veterinary Pain Management Market by Animal type
Chapter 6. North America Veterinary Pain Management Market by End-use
Chapter 7. North America Veterinary Pain Management Market by Indication
Chapter 8. North America Veterinary Pain Management Market by Product
Chapter 9. North America Veterinary Pain Management Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Boehringer Ingelheim International GmbH
- Bayer AG
- Zoetis, Inc.
- Merck & Co., Inc.
- Elanco Animal Health, Inc.
- Zomedica Corp. (Assisi Animal Health)
- Norbrook Laboratories Limited
- Ceva Santé Animale
- Dechra Pharmaceuticals PLC
- Vetoquinol SA (Soparfin SCA)
Methodology
LOADING...
